Why the study?
Intensive systolic BP control reduces cardiovascular disease risk but increases worsening renal function, leaving it unclear whether intensive BP control should be continued after worsening renal function occurs.
Does intensive systolic blood pressure treatment reduce cardiovascular disease and mortality in patients who develop worsening renal function?
Does intensive systolic blood pressure treatment reduce cardiovascular disease and mortality in patients who develop worsening renal function?
Intensive blood pressure control remains beneficial for reducing cardiovascular events and mortality even in patients who develop worsening renal function during treatment.
May support continuing intensive BP control despite worsening renal function; extends SPRINT but remains hypothesis-generating.
AIMS: Intensive systolic blood pressure (BP) control is associated with a lower risk of cardiovascular disease (CVD) but an increased risk of worsening renal function (WRF). This study aimed to investigate whether intensive BP control should be continued after WRF. METHODS AND RESULTS: We performed a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial). Worsening renal function was defined as an estimated glomerular filtration rate decline of ≥30% during follow-up from baseline. The associations between WRF, efficacy and safety outcomes, and BP treatment were evaluated using time-updated Cox proportional hazard models. Among 9211 participants included in this analysis, 1310 participants (14.2%) experienced WRF during follow-up. The intensive BP treatment significantly reduced the risk of the primary outcome compared with the standard BP treatment among patients with WRF [hazard ratio (HR): 0.54; 95% confidence interval (CI): 0.32-0.90] and without WRF (HR: 0.82; 95% CI: 0.68-0.98; Pinteraction = 0.224). In addition, the intensive BP treatment significantly reduced the risk of all-cause death among patients with WRF (HR: 0.40; 95% CI: 0.23-0.68), but not among patients without WRF (HR: 0.84; 95% CI: 0.67-1.07; Pinteraction = 0.046). Risks of safety events were similar between BP treatment groups among patients with and without WRF. Results were similar among participants who experienced WRF early or late during the intervention. CONCLUSION: Intensive BP treatment increased the risk of WRF compared with standard BP treatment. However, intensive BP treatment was associated with reduced risks of CVD and all-cause mortality compared with standard BP treatment in patients experiencing WRF, without increasing adverse events.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: